Nuvalent, Inc.
NUVL
Pozycja w akcjach
#2112
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Cena akcji
$123.96
Ostatnia synchronizacja: 2026-07-21
Kapitalizacja rynkowa
$9.75B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
27.56%
Kraj
US
Handel Nuvalent, Inc. (NUVL)
Kategoria
Healthcare
Liczba akcji w obrocie dla Nuvalent, Inc. (NUVL)
Liczba akcji w obrocie na dzień March 2026: 78.67M
Zgodnie z najnowszymi raportami finansowymi i ceną akcji Nuvalent, Inc., aktualna liczba akcji w obrocie to 78.67M. Na koniec December 2023 firma posiadała 58.22M akcji w obrocie. Liczba akcji w obrocie jest zwykle kształtowana przez podziały akcji i skupy akcji.
Historia liczby akcji w obrocie dla Nuvalent, Inc. (NUVL) od 2019 do 2026
Akcje w obrocie na koniec każdego roku
| Rok | Akcje w obrocie | Zmień |
|---|---|---|
| 2026 (TTM) | 78.67M | 18.46% |
| 2024 | 66.41M | 14.06% |
| 2023 | 58.22M | 17.22% |
| 2022 | 49.67M | 128.02% |
| 2021 | 21.78M | -4.73% |
| 2020 | 22.86M | -52.65% |
| 2019 | 48.28M | 0.00% |
Akcje w obrocie dla podobnych firm lub konkurentów
| Firma | Akcje w obrocie | Różnica | Kraj |
|---|---|---|---|
| 253.90M | 222.74% |
US
|
|
| 396.00M | 403.37% |
US
|
|
| 478.91M | 508.76% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -20.95% |
NL
|
